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Abstract 
 
‘Smart’ targeted drug carriers have long been sought after in the treatment of 
epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, 
relative to current clinical therapies (generally limited to surgery, radiation therapy, 
traditional chemotherapy, and EGF receptor inhibitors (EGFRIs)), of using such ‘smart’ 
targeted drug delivery systems. However, progress toward this goal has been challenged 
by the difficulty of creating a drug carrier that can autonomously detect and respond to 
tumor cells in the body. 
 
‘Smart’ micron-size drug-encapsulating epidermal growth factor (EGF)-sensitive 
liposomes for EGF-overexpressing cancer therapies have been developed and studied. 
These drug-encapsulating liposomes remain inert until they are exposed to an abnormal 
concentration of EGF. As a drug delivery system, these drug-encapsulating liposomes 
could release pharmaceutical agents specifically in the immediate neighborhood of 
tumors overexpressing EGF, thereby maximizing the effective amount of drug received 
by the tumor while minimizing the effective systemic toxicity of the drug. 
 
Additionally, quantitative mathematical models were developed to characterize 
multiple critical rate processes (including drug leakage from drug-encapsulating 
liposomes and distribution of (drug-encapsulating) liposomes in blood vessels) associated 
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with (drug-encapsulating) liposomes in general. These quantitative mathematical models 
provide a low-cost and rapid method for screening novel drug-encapsulating liposome 
compositions, configurations, and synthetic methods to identify liposome compositions, 
configurations, and synthetic methods that would deliver optimal performance. 
 
 The results provide a stepping stone toward the development of EGF-sensitive 
liposomes for clinical use. More generally, they also present implications for future 
development of other targeted drug delivery vehicles. 
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Chapter 1 
Introduction 
The human body is fundamentally dependent on the process of mitosis to renew 
itself and repair damage. Although in vivo cell replication is typically a closely monitored 
and regulated process, the regulatory checkpoints are not infallible. Inevitably, given 
sufficient time, a few cells with harmful genetic mutations may evade apoptosis and go 
on to replicate. Certain mutations may lead to subsequent uncontrolled cell replication 
and further harmful genetic mutations, which, if not detected and stopped by the immune 
system, may lead to cancer [1]. 
 
Epidermal growth factor (EGF)-overexpressing cancers (i.e., cancers, often 
advanced cancers, that produce abnormal amounts of EGF), along with other types of 
cancers, have collectively drawn enormous treatment expenses [1],[2],[3]; for example, 
the anticancer therapy market in the seven major pharmaceutical markets alone was 
valued at ~$24 billion in 2006 [4]. As overall life expectancies increase, the net incidence 
of cancers and the resulting treatment expenses will only continue to rise. Hence, 
research toward better cancer therapies is of critical importance. 
 
 Currently, conventional treatments are usually limited to surgery, radiation 
therapy, and generalized chemotherapy. Radiation therapy and generalized chemotherapy 
may result in significant side effects, including an increased risk of new tumor formation. 
Surgery, when feasible, is attendant with the risk of various surgical complications. 
Worse, combinations of treatments, usually radiation therapy and generalized 
chemotherapy, and recurring treatments, such as recurring radiation therapy, are often 
necessary, typically resulting in additional side effects and/or side effects of greater 
severity [1],[5],[6]. 
 
More recently, a newer approach for treating EGF-overexpressing cancers has 
been to use EGF receptor inhibitors (EGFRIs). The use of EGFRIs has increased the 
efficacy of drug therapy in treating EGF-overexpressing cancers and have also helped 
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reduce systemic side effects of treatment. However, EGFRIs may still cause significant 
systemic side effects, including skin, hair, nail, and mucosal side effects, as they still act 
generally in the body. Additionally, EGFRIs have not eliminated the need for 
conventional treatments such as radiation therapy [7],[8],[9]. 
 
To achieve the goal of maximizing the effectiveness of treatment while 
simultaneously minimizing undesirable systemic side effects, the ideal solution would be 
to use targeted drug delivery to release drugs specifically in the neighborhood of EGF-
overexpressing tumors [10]. As the incidence of cancers continues to rise as overall life 
expectancies increase, the development of such targeted clinical treatment methods for 
EGF-overexpressing cancers is of critical importance. 
 
One method for targeted drug delivery that has been researched and used 
extensively is to use drug-encapsulating liposomes triggered by such factors as 
ultrasound [11],[12]. However, drug-encapsulating liposomes triggered by such factors as 
ultrasound are generally attendant with the inconvenience and cost associated with the 
use of external medical equipment (e.g., an ultrasound machine). Also, it is not always 
clear (e.g., in the case of metastatic tumors) where the triggering factor (e.g., ultrasound 
waves) should be aimed when the tumors’ precise locations are unknown. 
 
 Since the goal is to treat EGF-overexpressing cancers, the ideal solution would be 
to develop drug-encapsulating liposomes triggered by abnormal amounts of EGF (i.e., 
EGF-sensitive liposomes). 
 
With the interdisciplinary application of principles from biology, chemistry, 
mathematics, and chemical engineering, functional EGF-sensitive drug-encapsulating 
liposomes have been successfully developed in vitro, and additionally, quantitative 
mathematical models that can help optimize (drug-encapsulating) liposomes in general 
have been developed. 
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This paper includes several main parts. First, the relevant experimental methods 
for preparation and characterization of EGF-sensitive drug-encapsulating liposomes are 
presented in Chapter 2. The experimental results are then analyzed and discussed in 
Chapter 3. Chapter 4 presents quantitative mathematical models characterizing key rate 
processes associated with industrial liposome preparation and the in vivo behavior of 
liposomes. Finally, Chapters 5 and 6 discuss the ramifications of the experimental and 
modeling studies presented. 
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Chapter 2 
Materials and Methods 
2.a  Epidermal Growth Factor (EGF) Receptor Modification 
p-toluic acid (Alfa Aesar) was added at a molar ratio of 1:1 to 1 µg EGF receptor 
(Invitrogen; supplied in 50 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 0.02% Triton 
X-100, 2 mM DTT, 50% glycerol; buffered at pH 7.5). The p-toluic acid and EGF 
receptor were then crosslinked with an EDC/NHS system (Pierce). 
 
Independently, in a separate container, methyl-PEG4-NHS ester (Pierce), an NHS-
activated polyethylene glycol compound, was added at a molar ratio of 1:1 to 1 µg EGF 
receptor (supplied in 50 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 0.02% Triton X-
100, 2 mM DTT, 50% glycerol; buffered at pH 7.5); the solution was then thoroughly 
mixed. 
 
The two independently prepared solutions above were then combined and 
thoroughly mixed to obtain a single solution containing both types of modified EGF 
receptors (i.e., toluic acid-crosslinked EGF receptors and methyl-capped polyethylene 
glycol-crosslinked EGF receptors) [13],[14]. 
 
2.b  Liposome Preparation 
0.2 mg egg phosphatidylcholine (Lipoid) was added to a polypropylene tube (BD 
Falcon); 1.5 ml chloroform (Mallinckrodt Baker) was then added to dissolve the egg 
phosphatidylcholine. The chloroform was then evaporated under a stream of nitrogen 
(Airgas), leaving a thin lipid film on the walls of the polypropylene tube which was 
redried twice under nitrogen to remove traces of residual solvent [15],[16],[17],[18],[19]. 
 
The dried lipid film was rehydrated in 0.2 ml Tris-buffered saline (Invitrogen; 20 
mM Tris, 150 mM NaCl, pH 7.4) containing 50 mM octyl-β-glucoside (Pierce); the 
rehydrated solution was then thoroughly mixed by vortexing. The mixed rehydrated 
solution was dialyzed for 36 h against three changes of buffer (consisting of Tris-buffered 
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saline, 30 mM benzamidine, HCl (Calbiochem), and 0.1 mM phenylmethylsulfonyl 
fluoride (Pierce)) to remove the detergent, allowing liposomes to form [15],[16],[18]. 
 
The resulting turbid liposome solution was mixed with sucrose (EMD 
Biosciences) to 40% (weight/volume), applied at the bottom of a sucrose gradient 
(consisting of 0.5 ml 40% sucrose solution, 1.5 ml 20% sucrose solution, and 1.5 ml 5% 
sucrose solution, in that order), and then centrifuged at 40,000 g for 3 h to remove 
residual detergent traces. Finally, fractions were collected from the top of the sucrose 
gradient [15],[16]. 
 
2.c  Drug-Encapsulating Liposome Preparation 
Drug-encapsulating liposomes were prepared by adding 1 mg/ml actinomycin D 
(EMD Biosciences), 14-hydroxydaunomycin, HCl (Calbiochem), or 4-amino-10-
methylfolic acid (Calbiochem) to the rehydrated lipid solution prepared above (see the 
section above titled Liposome Preparation), prior to the vortexing step [16]. 
 
2.d  Epidermal Growth Factor (EGF)-Sensitive Liposome Preparation 
EGF-sensitive liposomes were prepared by adding the combined modified EGF 
receptor solution prepared above (see the section above titled Epidermal Growth Factor 
(EGF) Receptor Modification) to the rehydrated lipid solution prepared above (see the 
section above titled Liposome Preparation), prior to the vortexing step [15],[17]. 
 
2.e  Modified Epidermal Growth Factor (EGF) Receptor Binding Assay 
The EGF-binding capability of modified EGF receptors prepared above (see the 
section above titled Epidermal Growth Factor (EGF) Receptor Modification) was 
assessed using radiolabeled [125I]EGF (PerkinElmer), as described [15]. 
 
2.f  Modified Epidermal Growth Factor (EGF) Receptor Dimerization Assay 
The dimerization capability of modified EGF receptors prepared above (see the 
section above titled Epidermal Growth Factor (EGF) Receptor Modification) was 
 5
assessed using SDS-PAGE with Coomassie blue staining (Invitrogen), as described 
[20],[21],[22]. 
 
2.g  Drug Release (In Vitro) Assay 
At various time points, free (unencapsulated) drug molecules and drug-
encapsulating liposomes (encapsulated drug molecules) in a drug-encapsulating liposome 
sample were phase separated; each time, a small (30 µl) aliquot was removed from each 
solution phase. The change in unencapsulated drug concentration in the sample over time 
was determined using 1H NMR spectroscopy (400 MHz, CDCl3) or UV-visible 
spectroscopy [23],[24],[25],[26],[27]. 
 
2.h  Liposome Size/Stability Assay 
 The effective diameter of EGF-sensitive liposomes was assessed at various points 
in the liposomes’ lifetime using dynamic light scattering (Brookhaven ZetaPALS) [28]. 
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Chapter 3 
Results 
The main goal was to develop modified epidermal growth factor (EGF) receptor-
bearing drug-encapsulating liposomes sensitive and responsive to EGF in the 
extraliposomal solution. After these drug-encapsulating liposomes were successfully 
developed, the goals were to, firstly, verify that said liposomes were sensitive and 
responsive to abnormal levels of EGF in the extraliposomal solution and, secondly, assess 
the specificity of said liposomes’ sensitivity to EGF (relative to other growth factors). 
Additional goals were to characterize the effective diameter and stability of said 
liposomes, to assess the EGF binding activity of the modified EGF receptors, and to 
characterize the dimerization activity of the modified EGF receptors. 
 
3.a  Modified EGF Receptor-Bearing Drug-Encapsulating Liposomes 
 The initial goal of this study was to assess whether the modified EGF receptor-
bearing drug-encapsulating liposomes (prepared as described in Materials and Methods) 
were sensitive and responsive to abnormal levels of EGF in the extraliposomal solution. 
The secondary goal was to assess whether these liposomes were sensitive specifically to 
EGF or if they would also undesirably respond significantly to other growth factors, such 
as vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF), in the 
extraliposomal solution. It was found that the liposomes were uniquely triggered by EGF, 
since only EGF could bind with high affinity to the EGF receptors. 
 
 To assess whether the liposomes were sensitive and responsive to EGF, modified 
EGF receptor-bearing actinomycin D-encapsulating liposomes were formulated and 1H 
NMR spectroscopy was used to monitor drug release from said liposomes when EGF was 
added or no EGF was added to the extraliposomal solution. The change in the 1H NMR 
absorption spectra between 7.5-8.0 ppm over time of each sample was recorded, and the 
results from each sample were compared [24]. 
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Due to differences in density, buffered saline liposome solutions naturally 
segregated into three distinct phases at equilibrium: a top liposomal solution phase 
containing, largely, intact liposomes as well as some free phosphatidylcholine lipid; a 
middle free phosphatidylcholine solution phase containing, largely, free lipid as well as 
some free/released drug (for drug-encapsulating liposome solutions); and a lower 
clumped phosphatidylcholine phase containing, largely, clumped phosphatidylcholine 
lipid as well as free/released drug (for drug-encapsulating liposome solutions). 
 
 
Figure 1 – Schematic showing phase segregation of a drug-encapsulating liposome 
suspension. 
 
 For both the experimental (actinomycin D-encapsulating liposomes with EGF 
added to the extraliposomal solution) and control (actinomycin D-encapsulating 
liposomes with no EGF added) samples, the absorption between 7.5-8.0 ppm of samples 
drawn from the free phosphatidylcholine solution phase increased from 0 d to 7 d after 
the beginning of the experiment (i.e., the time of addition of EGF, in the case of the 
experimental sample). However, the absorption of samples drawn from the free 
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phosphatidylcholine solution phase did not increase at the same rate in the experimental 
and control samples. 
 
At the beginning of the experiment, the absorption of samples drawn from the free 
phosphatidylcholine solution phase in the experimental sample was equal to the 
absorption of samples drawn from the free phosphatidylcholine solution phase in the 
control sample (see Figure 2, below). By 7 d after the beginning of the experiment, the 
absorption of samples drawn from the free phosphatidylcholine solution phase in the 
experimental sample was ~12% more than the absorption of samples drawn from the free 
phosphatidylcholine solution phase in the control sample. 
 
 In a given sample, when encapsulated actinomycin D (i.e., actinomycin D in 
liposomes) was released or leaked, the freed actinomycin D segregated from the 
liposomal solution phase into the lower phases (including the free phosphatidylcholine 
solution phase) of said sample. An increase in the amount/concentration of actinomycin 
D in the free phosphatidylcholine solution phase of a given sample resulted in a 
proportional increase in the absorption of samples drawn from said phase of said sample. 
Hence, a greater increase in absorption over a given amount of time (i.e., a higher rate of 
increase in absorption) translated to a larger amount of encapsulated actinomycin D being 
released over said amount of time (i.e., a higher rate of release of encapsulated drug). 
 
In the case of the control sample, there was a low intrinsic rate of leakage of 
encapsulated drug, resulting in a low rate of increase in absorption. In the case of the 
experimental sample, there was a higher, EGF-induced rate of release of encapsulated 
drug, resulting in a somewhat (~12%) higher rate of increase in absorption. Hence, the 
experimental results indicated that modified EGF receptor-bearing liposomes are (at least 
somewhat) sensitive and responsive to abnormal levels of EGF in the extraliposomal 
solution. Further experiments should be conducted to more precisely characterize the 
EGF sensitivity of these liposomes. 
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Figure 2 – Actinomycin D release from modified EGF receptor-bearing drug-
encapsulating liposomes. The absorption is shown as a function of time. Release was 
measured at an incubation temperature of 25 °C. Aliquots for 1H NMR spectroscopy 
were taken from experimental and control samples at various time points as previously 
described. 
 
To assess whether the liposomes were sensitive specifically to EGF or not, 
doxorubicin-encapsulating EGF-sensitive liposomes were formulated and UV-visible 
spectroscopy was used to monitor drug release from said liposomes when EGF was 
added, no EGF was added, VEGF was added, or FGF was added to the extraliposomal 
solution. An additional control involved using UV-visible spectroscopy to monitor non-
drug-encapsulating EGF-sensitive liposomes with EGF added to the extraliposomal 
solution. The change in the UV-visible absorption spectra at 490 nm λ over time of each 
sample was recorded, and the results from each sample were compared [25],[26]. 
 
For the experimental sample (doxorubicin-encapsulating EGF-sensitive liposomes 
with EGF added to the extraliposomal solution), the absorbance of samples drawn from 
the liposomal solution phase decreased from 0 min to 30 min after the beginning of the 
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experiment (i.e., the time of addition of EGF), and the absorbance of samples drawn from 
the free phosphatidylcholine solution phase increased from 0 min to 30 min after the 
beginning of the experiment (i.e., the time of addition of EGF). 
 
For the control samples (doxorubicin-encapsulating EGF-sensitive liposomes with 
no EGF added, doxorubicin-encapsulating EGF-sensitive liposomes with VEGF or FGF 
added to the extraliposomal solution, or non-doxorubicin-encapsulating EGF-sensitive 
liposomes with EGF added to the extraliposomal solution), the absorbance of samples 
drawn from the liposomal solution phase, as well as the absorbance of samples drawn 
from the free phosphatidylcholine solution phase, increased from 0 min to 30 min after 
the beginning of the experiment (i.e., the time of addition of EGF, FGF, or VEGF, if any 
growth factor was added to the extraliposomal solution). 
 
 In a given sample, when encapsulated doxorubicin (i.e., doxorubicin in 
liposomes) was released, the freed doxorubicin segregated from the liposomal solution 
phase into the lower phases (including the free phosphatidylcholine solution phase) of 
said sample. A decrease in the amount/concentration of doxorubicin in the liposomal 
solution phase of a given sample resulted in a proportional decrease in the absorbance of 
samples drawn from said phase of said sample. Also, in any given sample, there was a 
low intrinsic amount of liposome destabilization that resulted in lipids adopting less-
ordered arrangements. Thus, in the absence of a significant decrease in the 
amount/concentration of doxorubicin in the liposomal solution phase of a given sample, a 
low intrinsic amount of liposome destabilization resulted in an increase in the absorbance 
of samples drawn from said phase of said sample. Hence, a net decrease in absorbance 
translated to a significant amount of encapsulated doxorubicin being released. 
 
In the case of the control samples, there was no significant release of encapsulated 
drug, resulting in an increase in absorbance of liposomal solution phase samples. In the 
case of the experimental sample, there was a greater, EGF-induced release of 
encapsulated drug, resulting in a decrease in absorbance of liposomal solution phase 
samples. Hence, the experimental results indicated that EGF-sensitive liposomes are 
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specifically sensitive to EGF. Further experiments should be conducted to more precisely 
characterize the specificity and sensitivity of these liposomes. 
 
 
Figure 3 – Doxorubicin release from modified EGF receptor-bearing drug-
encapsulating liposomes. The absorbance is shown as a function of time. Release was 
measured at an incubation temperature of 25 °C. Aliquots for UV-visible spectroscopy 
were taken from experimental and control samples at various time points as previously 
described. 
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3.b  Particle Sizing of EGF-Sensitive Liposomes 
 The goal of this study was to characterize the particle size and stability of the 
EGF-sensitive liposomes. It was found that the liposomes had an effective diameter of 
~630 nm while inert. It was additionally found that the liposomes rapidly became 
unstable after being exposed to an abnormal concentration of EGF in the extraliposomal 
solution. 
 
 To assess the particle size and stability of the liposomes, EGF-sensitive liposomes 
were formulated and dynamic light scattering (DLS) was used to determine and monitor 
the particle size of the liposomes in buffered saline solution when EGF was added or no 
EGF was added to the extraliposomal solution. The particle size over time of the 
liposomes in each sample was determined and recorded. 
 
 The liposomes in the experimental sample initially had an effective diameter of 
~630 nm but rapidly became unstable (O(min)) after the addition of EGF to the solution, 
forming unordered lipid clumps with an effective diameter of ~20 μm. The liposomes in 
the control sample (no EGF added to solution) initially had an effective diameter of ~630 
nm and maintained this effective diameter over 24 hr. 
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Figure 4 – Inert size of the EGF-sensitive liposomes. 
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Figure 5 – Destabilized size of the clumped EGF-sensitive liposomes. 
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3.c  Binding Activity of Modified EGF Receptors 
 The aim of this study was to verify that the liposome-borne modified epidermal 
growth factor (EGF) receptors on EGF-sensitive liposomes were able to successfully bind 
to EGF with high affinity. It was found that said modified EGF receptors were indeed 
able to bind to EGF with high affinity. 
 
 To assess whether the liposome-borne modified EGF receptors were able to bind 
to EGF with high affinity, non-drug-encapsulating liposomes were formulated and liquid 
scintillation counting was used to determine radiolabeled EGF ([125I]EGF) distribution in 
liposome suspensions (which were prepared as previously described) when EGF-
sensitive liposomes (expt) or non-EGF-sensitive liposomes (ctrl) were used. Unbound 
ligands were removed by density gradient centrifugation to ensure accuracy of results. 
The radioactivity of each sample was recorded, and the results from each sample were 
compared [15]. 
 
 The experimental sample (EGF-sensitive liposomes with [125I]EGF added) 
displayed specific binding of [125I]EGF. The control sample (non-EGF-sensitive 
liposomes with [125I]EGF added) did not display binding of [125I]EGF. 
 
[125I]EGF Binding to Liposome-Borne Modified EGF Receptors
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120000
140000
1 2 3 4
Sample Number
c.
p.
m
. Ctrl
Expt
Top Bottom
 
 16
Figure 6 – [125I]EGF binding to liposome-borne modified EGF receptors. The c.p.m. 
is shown as a function of sample number. Binding assays were done as previously 
described on EGF-sensitive liposomes (expt) and non-EGF-sensitive liposomes (ctrl). 
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3.d  Dimerization Activity of Modified EGF Receptors 
 The aim of this study was to verify that the modified epidermal growth factor 
(EGF) receptors were able to dimerize in the presence of EGF. It was found that said 
modified EGF receptors were indeed able to dimerize in the presence of EGF. 
 
 To assess whether the modified EGF receptors were able to dimerize in the 
presence of EGF, modified EGF receptors were formulated (as described in Materials 
and Methods) and SDS-PAGE with Coomassie blue staining was used to determine 
whether modified EGF receptors dimerize upon binding of EGF. Modified (expt) or 
unmodified (ctrl) EGF receptors and EGF were incubated together and subsequently 
treated with DSS in order to make EGF-induced dimer formation irreversible. Additional 
controls involved modified or unmodified EGF receptors in the absence of EGF. The 
resulting proteins were analyzed using SDS-PAGE, and the results from each sample 
were compared [22]. 
 
 Both modified and unmodified EGF receptors formed dimers in the presence of 
EGF and did not dimerize in the absence of EGF. 
 18
 Figure 7 – Modified EGF receptor dimerization. Dimerization assays were performed 
for modified EGF receptors in the presence of EGF (expt, lane 3), modified EGF 
receptors only (ctrl, lane 4), unmodified EGF receptors in the presence of EGF (ctrl, lane 
1), unmodified EGF receptors only (ctrl, lane 2), and EGF only (baseline ctrl, lane 5). 
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Chapter 4 
Mathematical Models 
 After drug-encapsulating prototype EGF-sensitive liposomes were developed and 
experimentally assessed in vitro, the goal was to develop mathematical models to 
quantitatively analyze and describe key chemical processes associated with the industrial 
production and in vivo behavior of liposomes. 
 
 
Figure 8 – Schematic depicting various chemical processes associated with liposomes 
that can be simulated by quantitative mathematical modeling. 
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4.a  Model I: Drug Leakage from Multilamellar Liposome Vesicles (MLVs) 
Quantitative Mathematical Model I aims to model the rate process of drug leakage 
from drug-encapsulating liposomes, specifically MLVs. MLVs (instead of basic 
unilamellar liposome vesicles (ULVs); see Figure 8) were selected for modeling since 
their general configuration inherently minimizes drug leakage. As demonstrated below, 
given just four basic parameters, Quantitative Mathematical Model I allows one to 
quantitatively model and predict drug leakage over time for many drugs and many 
homogeneous MLV compositions. 
 
 
Figure 9 – Schematic of a typical multilamellar liposome vesicle (MLV). 
 
By the general species conservation equation, the rate of accumulation of species i 
within a specific region is a function of the rates at which said species i enters or is 
formed within said specific region. 
     ii
i R
t
C +⋅−∇=∂
∂ N      (A.1) 
where Ci represents the molar concentration of species i, Ni represents the molar flux of 
species i relative to fixed coordinates, and Ri represents the net rate, per unit volume, at 
which species i is formed [29]. 
 
 In the case of species i being a minor component in a pseudobinary liquid solution 
with constant density ρ and diffusivity Di, Eq. A.1 can be rewritten using Fick’s law as: 
     iii
i RCD
Dt
DC +∇= 2      (A.2) 
In spherical coordinates with no fluid flow and no net rate of formation of species 
i, Eq. A.2 becomes [29]: 
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For transient drug leakage from a spherically symmetric, homogeneous drug-
encapsulating multilamellar liposome vesicle (MLV) of radius R, we can reduce Eq. A.3 
to the following governing partial differential equation (PDE): 
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where C represents the concentration of the drug within the MLV. 
 
We have initial (IC) and boundary conditions (BCs): 
 
0 < r < R     t ≤ 0 C = C0    (A.5) 
r = 0 t ≥ 0  0=∂
∂
r
C    (A.6) 
r = R t ≥ 0   C
D
k
r
C C−=∂
∂    (A.7) 
where kC represents the mass transfer coefficient of the drug [29]. 
 
Scaling, we define the following dimensionless variables: 
R
r=η   
0
'
C
C=θ  t
R
D
2=τ    (A.8) 
 
Nondimensionalizing Eq. A.4-A.7, then, we obtain: 
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We now apply the following transformation: 
        ( ) ( )τηθτηθ ,'1, −=     (A.13) 
Eq. A.9-A.12 now become: 
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Using the finite Fourier transform (FFT) method, we seek a solution of the form: 
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The basis functions required are those satisfying Robin boundary conditions [29], 
specifically: 
( ) ( )η
ηλ
λ
ηφ n
C
n
C
n
D
Rk
D
Rk
sin
sin
1
2
2/1
2
⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎣
⎡
−
−
=  , nCn D
Rk λλ tan1 ⎟⎠
⎞⎜⎝
⎛ −= , n = 1, 2, …   (A.19) 
 
 Transforming the time and space derivatives in Eq. A.14, we obtain: 
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The initial condition transforms simply to: 
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 Accordingly, the complete transformed problem is: 
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 The solution of Eq. A.23 is: 
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The overall solution, then, using Eq. A.19 and A.24 in Eq. A.18, is: 
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 Inspection shows that the solution in Eq. A.25 consists of two main parts: a 
transient part which decays exponentially over time and a time-independent part which 
represents a steady state achieved as τ → ∞. Eq. A.25 is hence rewritten more simply 
using the steady-state solution as: 
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Finally, using Eq. A.26 in Eq. A.13, we obtain: 
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 Eq. A.27, in conjunction with Eq. A.8 and A.19, provides a representation of the 
concentration C of a given drug in a spherically symmetric, homogeneous drug-
encapsulating MLV of radius R as a function of radial position and time. Eq. A.27 hence, 
given four basic parameters: the initial (post-loading) concentration C0 of the drug in 
question in the MLV in question, the diffusivity D of said drug in said MLV, the radius R 
of said MLV, and the mass transfer coefficient kC of said drug, allows one to 
quantitatively model and predict drug leakage over time from drug-encapsulating MLVs 
for many drug and homogeneous MLV combinations. 
 
Model 1 Assumptions: spherically symmetric, homogeneous MLV; uniformly drug-
saturated MLV; Fick’s law valid; drug bulk concentration in the blood Cbulk, blood = 0 
compared to drug concentration in the liposome Cliposome; constant parameters (D, R, kC, 
ρ); no reactions 
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4.b  Model II: Vascular Mass Transfer of Liposomes 
 Quantitative Mathematical Model II aims to model the rate process of the mass 
transfer of (drug-encapsulating or non-drug-encapsulating) liposomes in blood vessels. 
As demonstrated below, given just six basic parameters, Quantitative Mathematical 
Model II allows one to quantitatively model and predict the vascular mass transfer of 
many types of liposomes. 
 
 
Figure 10 – Schematic of a blood vessel showing mass transfer coefficients. 
 
By the general linear momentum conservation equation, the rate of change of 
momentum at a material point in a fluid (such as blood) is a function of the body forces 
and stresses acting on that body of fluid. 
    σgv ⋅∇+= ρρ
Dt
D      (B.1) 
where σ is the stress tensor [29]. 
 
 In the case of an incompressible Newtonian fluid with constant viscosity and 
density, Eq. B.1 can be rearranged and rewritten as the Navier-Stokes equation [29]: 
vgv 2∇+∇−= μρρ P
Dt
D     (B.2) 
or, equivalently, 
vv 2∇+−∇= μρ P
Dt
D      (B.3) 
where P is the dynamic pressure [29]. 
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 In cylindrical coordinates with fully developed, unidirectional flow, Eq. B.3 
reduces to [29]: 
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which for steady, axisymmetric flow becomes the following ODE: 
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Integrating and applying a symmetry boundary condition at r = 0, we obtain: 
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Integrating again and applying a no-slip boundary condition at r = R (where R is 
the vessel radius), we obtain: 
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 Eq. B.7 can be expressed using the mean velocity U as: 
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The velocity profile expressed in Eq. B.8 can then be applied in the general 
species conservation equation for a pseudobinary liquid solution with constant 
diffusivity, which is: 
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 In cylindrical coordinates, assuming a large Péclet number (neglecting axial 
diffusion), Eq. A.2 becomes: 
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or, equivalently, using Eq. B.8 in Eq. B.10, we obtain the following governing partial 
differential equation for liposome distribution in a vessel: 
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where C represents the liposome concentration in the vessel. 
 
 Integrating Eq. B.10 over r, we obtain [29]: 
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where Nr represents the liposome flux. 
 
 Using the “mixing cup” quantity Cb (see Deen [29]): 
          ∫
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A z
A z
b dAv
dACv
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where A is the cross-sectional area, we can rewrite the left-hand side of Eq. B.12 as [29]: 
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where U is the mean velocity as given in Eq. B.9. 
 
 The liposome flux from the blood to the vessel wall is given by [29]: 
                                                                ( )
Rrbcr
CCkN =−=        (B.15) 
and the liposome flux through the vessel wall is given by [29]: 
      ( )tRrmr CCkN −= =        (B.16) 
where Ct is the liposome concentration in the tissue at the outer vessel wall surface.  
Finally, the liposome flux in the tissue is written as: 
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ttr CkN =         (B.17) 
 
Combining Eq. B.12, B.14, and B.15, we obtain [29]: 
  ( )Rrbcb CCRUkdzdC =−−= 2        (B.18) 
 
 The liposome concentration at the inner vessel wall surface C|r=R is now 
eliminated by equating the three expressions for the flux, Eq. B.15, B.16, and B.17. 
Rearranging, we obtain: 
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 Using Eq. B.19 in Eq. B.18, then, the final differential equation for the bulk 
concentration Cb is: 
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where Co is the initial liposome (inlet) concentration. 
 
 The solution of Eq. B.20 is: 
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Eq. B.22, in conjunction with Eq. B.9, provides a representation of the mass 
transfer of (drug-encapsulating or non-drug-encapsulating) liposomes in a blood vessel. 
The model hence, given six basic parameters: the radius R of the vessel, the mean 
velocity U of fluid flow in said vessel, the initial liposome inlet concentration Co, and the 
mass transfer coefficients kc, km, and kt of the liposomes in the blood, vessel wall, and 
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tissue space, respectively, allows one to quantitatively model and predict the mass 
transfer of liposomes in a blood vessel as a function of axial position for many types of 
liposomes. 
 
 The above model can be extended by using first principles to compute the mass 
transfer coefficient kc (see references [29],[47],[48]). 
 
Model 2 Assumptions: incompressible Newtonian blood; Fick’s law valid; fully 
developed blood flow; unidirectional, axisymmetric blood flow; steady blood flow; large 
Péclet number (Pe = 2*U*R/D ~ 2*(0.001 m/s)*(5*10-6 m)/(10-12 m2/s) = 104 >> 1 in a 
capillary); = constant; constant parameters (D, R, k/dzdP C, km, kt, µ, ρ); no reactions 
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4.c  Model III: Early Post-Administration Tissue Distribution of Liposomes 
 Quantitative Mathematical Model III aims to model the rate process of the early 
post-administration tissue distribution of (drug-encapsulating or non-drug-encapsulating) 
liposomes. As demonstrated below, given just two basic parameters, Quantitative 
Mathematical Model III allows one to easily quantitatively model and predict the early 
tissue spatial and temporal distribution of many types of liposomes. 
 
 The following governing partial differential equation (PDE) applies for an 
instantaneous point source of liposomes (i.e., from an injection): 
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where C represents the liposome concentration [29]. 
 
 We can also apply conservation of mass to write: 
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where s is the total amount of liposomes added (i.e., injected) at t = 0 [29]. 
 
 Applying Eq. C.1-C.2 with the appropriate boundary and initial conditions (C = 0 
at x, y, and z at ±∞ and at t = 0) and solving per Deen [29]: 
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 For a continuous point source of liposomes (i.e., from an IV or a drug delivery 
device), Eq. C.3 can be integrated over time to obtain the corresponding continuous point 
source solution. For a constant release rate from the point source, the solution is [29]: 
( ) ⎟⎟⎠
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r
Dr
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where q is the constant liposome release rate from the IV or drug delivery device. 
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Eq. C.3 and Eq. C.4, above, provide a representation of the liposome 
concentration C as a function of elapsed time t and radial position r from the liposome 
point source for short times (i.e., low values of elapsed time). Eq. C.3 and Eq. C.4 hence, 
given two basic parameters: the total amount s of liposomes added or the liposome 
release rate q, and the effective diffusivity D of said liposomes, allow one to 
quantitatively model and predict the early post-administration tissue distribution of 
liposomes for many types of liposomes. 
 
 A similar approach can also be used to formulate a model for continuous 
liposome release from an implanted bolus. Such a model could be solved numerically via 
finite element analysis [30]. 
 
 The MATLAB code in Appendix A can be used (with slight modifications as 
necessary) to numerically evaluate and graphically portray the liposome concentration C 
as a function of elapsed time t and radial position r from the liposome point source for a 
constant liposome release rate q. The code can easily be extended to cover the case of an 
instantaneous point source. 
 
 A plot of the liposome concentration C as a function of elapsed time t at various 
liposome release rates q is shown in Figure 11, below: 
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Figure 11 – Early post-administration tissue distribution of liposomes. The liposome 
concentration is shown as a function of time at various liposome release rates. D ~ 
10-12 m2/s 
 
 A plot of the liposome concentration C as a function of elapsed time t at various 
values of radial position r is shown in Figure 12, below: 
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Figure 12 – Early post-administration tissue distribution of liposomes. The liposome 
concentration is shown as a function of time at various values of radial position. 
 
 A plot of the liposome concentration C as a function of radial position r at various 
values of elapsed time t is shown in Figure 13, below: 
 
 
Figure 13 – Early post-administration tissue distribution of liposomes. The liposome 
concentration is shown as a function of radial position at various values of elapsed 
time. 
 
 Broadly, the plots shown in Figures 11, 12, and 13 above, are consistent with 
qualitative expectations. At a given radial position, the concentration increases with 
elapsed time. At a given elapsed time point, the concentration decreases with increasing 
radial distance from the liposome point source. Also, at a given radial position and 
elapsed time point, the concentration increases with increasing liposome release rate from 
the point source. 
 
Model 3 Assumptions: Fick’s law valid; no bulk flow; constant parameters (D, q); short 
(early) times; no reactions 
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4.d  Model IV: Overall Pharmacokinetics of Liposomes 
 Quantitative Mathematical Model IV aims to model the overall pharmacokinetics 
of liposomes in the body. 
 
 The governing differential equations for a two-compartment open model are [31]: 
                                       IVCkVCkVCk
dt
dCV PPCTTPPPP +−+−= 2112      (D.1) 
TTPP
T
T VCkVCkdt
dCV 2112 −=       (D.2) 
 
 The general solution for the case where I = 0 (for an I.V. bolus) is of the form: 
                                                                          (D.3) ttP BeAeC
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From Eq. D.4, Eq. D.5, and Eq. D.6, above, the effective plasma to tissue (k12), 
tissue to plasma (k21), and clearance from plasma (kC) rate constants can be determined 
from the empirically determined constants A, B, α, and β (which can be evaluated by 
fitting Eq. D.3 to experimental data on the liposome plasma concentration (CP) as a 
function of time). A similar approach can be used with other compartmental models as 
required by the experimental data. Knowledge of these rate constants (k12, k12, kC) is 
helpful in liposome bioavailability and toxicity studies. 
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Figure 14 – Schematic showing the basic components of a two-compartment open 
pharmacokinetic model. 
 
 The MATLAB code in Appendix A can be used (with slight modifications as 
necessary) to fit Eq. D.3 to experimental CP data using nonlinear least squares regression 
fitting, as shown in Figure 15, below (experimental data from references [32],[33],[34]): 
 
 
 36
Figure 15 – Liposome clearance from blood. The liposome plasma concentration is 
shown as a function of time. 
 
Model 4 Assumptions: I = 0 (I.V. bolus); two compartments; constant parameters (k12, 
k21, kc, VP, VT) 
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4.e  Model V: High-Throughput Production of Liposomes 
 Quantitative Mathematical Model V aims to model the rate process of continuous, 
high-throughput production of liposomes in a plug flow reactor (PFR) [35]. 
 
 The relevant reaction may be represented as [36],[37],[38]: 
100 Modified EGF Receptors (MER) (l) + 10000 Drug (DRG) (l) + 80000 Lipid (LIP) (s) 
Æ Liposome (DEL) (l) 
(E.1) 
 
In a plug flow reactor assumed to be ideal, the governing mole balance equation 
for species j is, per Fogler [39]: 
j
j r
dV
dF =         (E.2) 
 Assuming a low feed flow rate u, the change in thickness of the deposited lipid 
film on the walls of the reactor is negligible over short time scales. Hence, Eq. E.2 can be 
rewritten to evaluate the change in concentration of species j Cj with reactor position L: 
u
r
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dC jj =         (E.3) 
 
 For constant radius and flow, the surface reaction rate can be related to changes in 
the bulk concentrations as follows: 
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where Nj represents the number of moles of species j and A is the area, V is the volume, r 
is the radius, and d is the diameter of the reactor. 
 
 Then, assuming pseudo-second order kinetics with a large excess of deposited 
lipid (i.e., [LIP] ~ constant for short times) and using the reaction stoichiometry for MER, 
DRG, and DEL given in Eq. E.1 [36],[37],[38], we obtain the following governing 
differential equations for the solution-phase species: 
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where k is the reaction rate coefficient. 
 
 The MATLAB code in Appendix A can be used (with slight modifications as 
necessary) to numerically evaluate Eqs. E.5-E.7 and graphically portray the solution-
phase species concentrations C as functions of reactor position L, as shown in Figures 16, 
17, and 18, below: 
 
Figure 16 – Drug-encapsulating liposome (DEL) production in a PFR. The solution-
phase modified EGF receptor (MER) and drug (DRG) concentrations are shown as 
functions of reactor position. Initial conditions at reactor inlet: [MER] = 500 arbitrary 
units (a.u.); [DRG] = 50000 a.u.; [DEL] = 0 a.u. 
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Figure 17 – Drug-encapsulating liposome (DEL) production in a PFR. The solution-
phase modified EGF receptor (MER) concentration is shown as a function of 
reactor position. 
 
Figure 18 – Drug-encapsulating liposome (DEL) production in a PFR. The solution-
phase drug-encapsulating liposome (DEL) concentration is shown as a function of 
reactor position. 
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Broadly, the plots shown in Figures 16, 17, and 18, above, are consistent with 
qualitative expectations. The concentrations of MER and DRG decrease with increasing 
reactor position, and the concentration of DEL increases correspondingly with increasing 
reactor position. 
 
Model 5 Assumptions: ideal plug flow reactor; low feed flow rate; short (early) times; 
adsorption and desorption not rate-limiting; pseudo-second order kinetics; constant 
parameters (k, r, u) 
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Chapter 5 
Discussion 
 In summary, this work reports the development of drug-encapsulating EGF-
sensitive liposomes for EGF-overexpressing cancer therapies. Experimental methods 
described herein produce EGF sensitivity in (drug-encapsulating) liposomes by 
introducing liposome-borne chemically modified EGF receptors. Quantitative 
mathematical models described herein characterize and describe various critical rate 
processes associated with drug-encapsulating liposomes and can be used to help design 
improved drug-encapsulating liposomes. The results represent a significant stepping 
stone toward the use of drug-encapsulating EGF-sensitive liposomes for EGF-
overexpressing cancer therapies in clinical practice. 
 
5.a  Some Complications with the In Vitro Model 
 The prototypical experimental setup described herein demonstrates qualitative 
control of EGF sensitivity in liposomes. The actual in vivo processes may be too 
complicated to allow specific quantification based only on this initial in vitro study. The 
prototypical in vitro setup has a number of obvious limitations and departures from in 
vivo physiology. The results are, nevertheless, meaningful because they allow one to 
characterize the liposomes’ basic function in the absence of complicating factors, and 
they clearly demonstrate the sensitivity of the liposomes to EGF in the extraliposomal 
solution. Additionally, the results show that the liposomes are able to clearly distinguish 
between EGF and other growth factors such as VEGF and FGF. 
 
5.b  General Liposome Design and Synthesis Optimization 
 The quantitative mathematical models described herein are potentially of use 
generally in optimizing the design and synthesis of a broad array of (EGF-sensitive or 
non-EGF-sensitive) (drug-encapsulating) liposomes. Figures 11, 12, 13, 15, 16, 17, and 
18 suggest the applicability of said quantitative mathematical models in assessing the 
drug leakage, vessel mass transfer, and industrial production rate processes, as well as the 
in vivo pharmacokinetics, of said broad array of (drug-encapsulating) liposomes. 
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Prior efforts by other researchers in assessing the drug leakage, vessel mass 
transfer, and industrial production rate processes of liposomes have largely relied on 
direct experimental testing and analysis [40]. As a result, analysis and testing of novel 
liposome compositions, configurations, or synthetic methods with the goal of identifying 
optimal compositions and configurations (to, for example, minimize drug leakage and 
achieve a favorable mass transfer profile in blood vessels) or optimal synthetic methods 
(to, for example, maximize the speed and efficiency of liposome production, and hence 
minimize the liposomes’ manufacturing costs) has been somewhat limited. 
 
With the quantitative mathematical models described herein, many more drug-
encapsulating liposome compositions, configurations, and synthetic methods could be 
assessed rapidly and at low cost. In one potential methodology, for instance, quantitative 
modeling results could be used as a preliminary filter in screening a large number of 
drug-encapsulating liposome compositions, configurations, or synthetic methods in a 
high-throughput fashion. Compositions, configurations, or synthetic methods determined 
to be promising based on the modeling results could then be further assessed with 
previous evaluation techniques. 
 
With the above potential methodology, optimal compositions, configurations, and 
synthetic methods that would have gone unidentified with previous evaluation and testing 
methods might very likely be identified by the application of the quantitative 
mathematical models described herein in conjunction with previous evaluation 
techniques. Additionally, other potential methodologies of value involving the 
quantitative mathematical models described herein may also be devised by those skilled 
in the art. 
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Chapter 6 
Conclusions 
In conclusion, the integrative in vitro experiments and quantitative mathematical 
models presented in this work, utilizing principles and procedures from biology, 
chemistry, mathematics, and chemical engineering, yield significant scientific and 
preclinical insights into a novel growth factor-sensitive targeted drug delivery system. 
 
By incorporating liposome-borne chemically modified EGF receptors, liposomes 
can be made to have EGF sensitivity, allowing drug release to be triggered from drug-
encapsulating liposomes by abnormal concentrations of EGF. By quantitatively modeling 
multiple critical rate processes associated with the function and synthesis of drug-
encapsulating liposomes, drug-encapsulating EGF-sensitive liposomes, as well as a broad 
array of drug-encapsulating liposomes in general, can be assessed and optimized. 
 
This work demonstrates the ability of modified EGF receptor-bearing liposomes 
to function as EGF-sensitive liposomes in vitro. Future research building on this work 
should involve further preclinical and clinical testing of the in vivo efficacy and toxicity 
of these liposomes. 
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Appendix A 
MATLAB Code 
 
function Model_III 
clear all; 
close all; 
  
%Initialize counter 
n=1; 
  
%Set time vector 
t=linspace(0.01,5,1000); 
  
%Set parameters 
a=6.25; 
r=5; 
D=2; 
  
while n < 1001 
    c(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=12.5; 
r=5; 
D=2; 
  
while n < 1001 
    c2(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=25; 
r=5; 
D=2; 
  
while n < 1001 
    c3(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
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%Re-set parameters 
a=50; 
r=5; 
D=2; 
  
while n < 1001 
    c4(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=100; 
r=5; 
D=2; 
  
while n < 1001 
    c5(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Plot figure 
figure(1) 
plot(t,c,'-.',t,c2,'-.',t,c3,'-.',t,c4,'-.',t,c5,'-.'); 
title('Early post-administration tissue distribution of liposomes'); 
xlabel('Time, t'); 
ylabel('Concentration, C'); 
legend('r=5; D=2; q/4*Pi*D=6.25','r=5; D=2; q/4*Pi*D=12.5','r=5; D=2; 
q/4*Pi*D=25','r=5; D=2; q/4*Pi*D=50','r=5; D=2; q/4*Pi*D=100'); 
  
%Clear all values 
clear all; 
  
%Initialize counter 
n=1; 
  
%Set time vector 
t=linspace(0.01,5,1000); 
  
%Set parameters 
a=25; 
r=1.25; 
D=2; 
  
while n < 1001 
    c(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
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%Re-set parameters 
a=25; 
r=1.875; 
D=2; 
  
while n < 1001 
    c2(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=25; 
r=2.5; 
D=2; 
  
while n < 1001 
    c3(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=25; 
r=5; 
D=2; 
  
while n < 1001 
    c4(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=25; 
r=20; 
D=2; 
  
while n < 1001 
    c5(n)=(a/r)*erfc(r/(2*(D*t(n))^(1/2))); 
    n=n+1; 
end 
  
%Plot figure 
figure(2) 
plot(t,c,'-.',t,c2,'-.',t,c3,'-.',t,c4,'-.',t,c5,'-.'); 
title('Early post-administration tissue distribution of liposomes'); 
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xlabel('Time, t'); 
ylabel('Concentration, C'); 
legend('r=1.25; D=2; q/4*Pi*D=25','r=1.875; D=2; q/4*Pi*D=25','r=2.5; 
D=2; q/4*Pi*D=25','r=5; D=2; q/4*Pi*D=25','r=20; D=2; q/4*Pi*D=25'); 
  
%Clear all values 
clear all; 
  
%Initialize counter 
n=1; 
  
%Set position vector 
r=linspace(1,5,1000); 
  
%Set parameters 
a=6.25; 
t=5; 
D=2; 
  
while n < 1001 
    c(n)=(a/r(n))*erfc(r(n)/(2*(D*t)^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=6.25; 
t=50  ;
D=2; 
  
while n < 1001 
    c2(n)=(a/r(n))*erfc(r(n)/(2*(D*t)^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=6.25; 
t=500; 
D=2; 
  
while n < 1001 
    c3(n)=(a/r(n))*erfc(r(n)/(2*(D*t)^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
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a=6.25; 
t=5000; 
D=2; 
  
while n < 1001 
    c4(n)=(a/r(n))*erfc(r(n)/(2*(D*t)^(1/2))); 
    n=n+1; 
end 
  
%Reset counter 
n=1; 
  
%Re-set parameters 
a=6.25; 
t=50000; 
D=2; 
  
while n < 1001 
    c5(n)=(a/r(n))*erfc(r(n)/(2*(D*t)^(1/2))); 
    n=n+1; 
end 
  
%Plot figure 
figure(3) 
plot(r,c,'-.',r,c2,'-.',r,c3,'-.',r,c4,'-.',r,c5,'-.'); 
title('Early post-administration tissue distribution of liposomes'); 
xlabel('Position, r'); 
ylabel('Concentration, C'); 
legend('t=5; D=2; q/4*Pi*D=6.25','t=50; D=2; q/4*Pi*D=6.25','t=500; 
D=2; q/4*Pi*D=6.25','t=5000; D=2; q/4*Pi*D=6.25','t=50000; D=2; 
q/4*Pi*D=6.25'); 
  
%Clear all at the end of the program 
clear all; 
 
 
function Model_IV 
clear all; 
close all; 
  
%Input experimental data 
C=[42 31 21 15 9 4.1 2.8 1.9 0.99]; 
t=[0.25 0.5 1 1.5 2 4 8 12 16]; 
  
[alpha,R,J]=nlinfit(t,C,@fit,[1 1 1 1]); 
  
alpha 
  
%Plot nonlinear regression fit 
figure(1),clf, 
semilogy(t,C,'.'); 
hold on; 
semilogy(t,alpha(1)*exp(-alpha(2)*t)+alpha(3)*exp(-alpha(4)*t),'-.'); 
title('Liposome clearance from blood'); 
xlabel('Time, t'); 
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ylabel('Concentration, C'); 
legend('C_p=47.2e^-^1^.^1^t+5.6e^-^0^.^1^t'); 
hold off; 
  
%Clear all at the end of the program 
clear all; 
  
function alwong_Model_IV = fit(alpha,t) 
alwong_Model_IV=alpha(1)*exp(-alpha(2)*t)+alpha(3)*exp(-alpha(4)*t); 
 
 
function Model_V 
clc; 
clear all; 
close all; 
  
%Set parameters 
d=0.02; 
L=0.1E-5; 
u=2.5; 
k=0.2; 
  
%Set initial conditions 
ICs=[500; 50000; 0]; 
  
%Set length to solve the system 
z=linspace(0,L,20000); 
  
%Set numerical solver options 
options=odeset('NonNegative',[1 2 3]); 
  
[length C]=ode15s(@equations,z,ICs,options,d,u,k); 
  
%Plot liquid-phase concentrations as function of PFR position 
figure(1) 
plot(length,C(:,1),'-.',length,C(:,2),'-.'); 
title('Drug-encapsulating liposome (DEL) production in a PFR'); 
xlabel('PFR Position, L'); 
ylabel('Solution-Phase Concentration, C'); 
legend('[MER]','[DRG]'); 
axis([0 0.1E-6 0 5E4]); 
  
figure(2) 
plot(length,C(:,1),'-.'); 
title('Drug-encapsulating liposome (DEL) production in a PFR'); 
xlabel('PFR Position, L'); 
ylabel('Solution-Phase Concentration, C'); 
legend('[MER]'); 
axis([0 0.1E-6 0 500]); 
  
figure(3) 
plot(length,C(:,3),'-.'); 
title('Drug-encapsulating liposome (DEL) production in a PFR'); 
xlabel('PFR Position, L'); 
ylabel('Solution-Phase Concentration, C'); 
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legend('[DEL]'); 
axis([0 0.1E-6 0 10]); 
  
%Clear all at the end of the program 
clear all; 
  
function alwong_Model_V = equations(L,C,d,u,k) 
dCdt=zeros(3,1); 
Mer=C(1); 
Drg=C(2); 
Del=C(3); 
  
dCdt(1)=-(400/d)*k*Mer*Drg; 
dCdt(2)=-(40000/d)*k*Mer*Drg; 
dCdt(3)=(4/d)*k*Mer*Drg; 
  
alwong_Model_V=(1/u)*dCdt; 
return; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
Appendix B 
Mathematical Models Supplement 
B.a  Simplified Drug Leakage from Multilamellar Liposome Vesicles (MLVs) 
 This section presents a simplified version of Mathematical Model I in the limiting 
case where any drug reaching the external surface of the MLV is almost instantaneously 
convected away due to a high rate of convection in the fluid outside the MLV (i.e., C ≈ 0 
at r = R). 
 
 The governing PDE in this case, with IC and BCs, is: 
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 Scaling and nondimensionalizing, we obtain: 
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η = 1 τ ≥ 0  θ’ = 0      (a.9) 
 
We now apply the transformation: 
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 Then: 
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Using the finite Fourier transform (FFT) method, we seek a solution of the form: 
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Per Deen [29], the basis functions required are those satisfying Dirichlet boundary 
conditions, specifically: 
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The initial condition transforms simply to: 
( ) 00 =nθ         (a.19) 
 
 Accordingly, the complete transformed problem is: 
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 The solution of Eq. a.20 is: 
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The overall solution, then, using Eq. a.16 and a.21 in Eq. a.15, is: 
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 Following the analysis of Deen [29], inspection shows that the solution in Eq. 
a.22 consists of two main parts: a transient part which decays exponentially over time and 
a time-independent part which represents a steady state achieved as τ → ∞. Eq. a.22 is 
hence rewritten more simply using the steady-state solution as: 
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Finally, using Eq. a.23 in Eq. a.10, we obtain: 
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 Eq. a.24, in conjunction with Eq. a.5, provides a representation of the 
concentration C of a given drug in a spherically symmetric, homogeneous drug-
encapsulating MLV of radius R as a function of radial position and time. Eq. a.24 hence, 
given three basic parameters: the initial (post-loading) concentration C0 of the drug in 
question in the MLV in question, the diffusivity D of said drug in said MLV, and the 
radius R of said MLV, allows one to easily quantitatively model and predict drug leakage 
over time from drug-encapsulating MLVs for many drug and homogeneous MLV 
combinations. 
 
 54
 The following MATLAB code can be used (with slight modifications as 
necessary) to numerically evaluate and graphically portray the dimensionless 
concentration θ’ of a given drug in a spherically symmetric, homogeneous drug-
encapsulating MLV of radius R as a function of dimensionless radial position η and 
dimensionless time τ: 
 
function Model_B_I 
clear all; 
close all; 
  
%Initialize counter 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
n=1:100; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.005); 
    temp=cumsum(a); 
    s(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.01); 
    temp=cumsum(a); 
    sa(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.05); 
 55
    temp=cumsum(a); 
    sb(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.1); 
    temp=cumsum(a); 
    sc(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.15); 
    temp=cumsum(a); 
    sd(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.2); 
    temp=cumsum(a); 
    se(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
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%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.3); 
    temp=cumsum(a); 
    sf(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'tau' value 
c=1; 
  
%Set initial dimensionless position 
r=0.001; 
  
while r < 1.001 
    a=(((-2)*(-1).^n)./(r*n*pi)).*sin(r*n*pi).*exp(-(n.^2)*pi*pi*.4); 
    temp=cumsum(a); 
    sg(c)=temp(1,100); 
    rv(c)=r; 
    r=r+0.001; 
    c=c+1; 
end 
  
%Plot figure 
figure(1) 
plot(rv,s,'-.',rv,sa,'-.',rv,sb,'-.',rv,sc,'-.',rv,sd,'-.',rv,se,'-
.',rv, ... 
    sf,'-.',rv,sg,'k-.'); 
title('Drug leakage from a drug-encapsulating MLV of radius R'); 
xlabel('Dimensionless Radial Position, r/R'); 
ylabel('Dimensionless Concentration, C/C_0'); 
legend('Dt/R^2 = 
0.005','0.01','0.05','0.10','0.15','0.20','0.30','0.40'); 
axis([0.01 .99 -0.01 .99]); 
  
%Clear all values 
clear all; 
  
%Initialize counter 
c=1; 
  
%Set initial dimensionless time 
t=0.001; 
  
n=1:100; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.005*n*pi)).*sin(.005*n*pi).*exp(-
(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    s(c)=temp(1,100); 
 57
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'eta' value 
c=1; 
  
%Set initial dimensionless time 
t=0.001; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.25*n*pi)).*sin(.25*n*pi).*exp(-
(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    sa(c)=temp(1,100); 
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'eta' value 
c=1; 
  
%Set initial dimensionless time 
t=0.001; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.5*n*pi)).*sin(.5*n*pi).*exp(-(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    sb(c)=temp(1,100); 
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'eta' value 
c=1; 
  
%Set initial dimensionless time 
t=0.001; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.75*n*pi)).*sin(.75*n*pi).*exp(-
(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    sc(c)=temp(1,100); 
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'eta' value 
c=1; 
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%Set initial dimensionless time 
t=0.001; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.95*n*pi)).*sin(.95*n*pi).*exp(-
(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    sd(c)=temp(1,100); 
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Reset counter for next 'eta' value 
c=1; 
  
%Set initial dimensionless position 
t=0.001; 
  
while t < 1.001 
    a=(((-2)*(-1).^n)./(.99*n*pi)).*sin(.99*n*pi).*exp(-
(n.^2)*pi*pi*t); 
    temp=cumsum(a); 
    se(c)=temp(1,100); 
    tv(c)=t; 
    t=t+0.001; 
    c=c+1; 
end 
  
%Plot figure 
figure(2) 
plot(tv,s,'-.',tv,sa,'-.',tv,sb,'-.',tv,sc,'-.',tv,sd,'-.',tv,se,'-.'); 
title('Drug leakage from a drug-encapsulating MLV of radius R'); 
xlabel('Dimensionless Time, Dt/R^2'); 
ylabel('Dimensionless Concentration, C/C_0'); 
legend('r/R = 0.005','0.25','0.50','0.75','0.95','0.99'); 
axis([0 .99 -0.01 1.01]); 
  
%Clear all at the end of the program 
clear all; 
 
Code Block B.a – MATLAB code for numerically evaluating and graphically 
portraying Eq. a.24. 
 
A plot of the dimensionless concentration θ’ of a given drug in a MLV as a 
function of dimensionless radial position η at various values of dimensionless time τ is 
shown in Figure 19, below: 
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Figure 19 – Drug leakage from a drug-encapsulating MLV of radius R. The 
dimensionless drug concentration is shown as a function of dimensionless radial 
position at various values of dimensionless time. 
 
A plot of the dimensionless concentration θ’ of a given drug in a MLV as a 
function of dimensionless time τ at various values of dimensionless radial position η is 
shown in Figure 20, below: 
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Figure 20 – Drug leakage from a drug-encapsulating MLV of radius R. The 
dimensionless drug concentration is shown as a function of dimensionless time at 
various values of dimensionless radial position. 
 
Broadly, the plots shown in Figures 19 and 20, above, are consistent with 
qualitative expectations. At a given radial position, the concentration decays with scaled 
time. At a given scaled time point, the concentration decreases with increasing radial 
distance from the center of the drug-encapsulating MLV. Also, since the results and 
trends shown in Figures 10 and 11, above, involve dimensionless (normalized/scaled) 
quantities, they – and the results and trends one could obtain from similar plots – are 
applicable to any drug-encapsulating MLV system that Eq. a.24 is applicable to. 
 
Model B.a Assumptions: spherically symmetric, homogeneous MLV; uniformly drug-
saturated MLV; Fick’s law valid; drug bulk concentration in the blood Cbulk, blood = 0 
compared to drug concentration in the liposome Cliposome; high rate of convection in fluid 
outside MLV (hence C ≈ 0 at r = R); constant parameters (D, R, ρ); no reactions 
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B.b  Vascular Distribution of Liposomes 
 This section extends Mathematical Model II by using first principles to compute 
the mass transfer coefficient kc and model the liposome distribution in a blood vessel in 
the limiting case where any drug reaching the inner vessel wall surface is almost 
instantaneously leaked into the tissue space (i.e., C ≈ 0 at r = R). 
 
 The governing PDE in this case, with BCs, is: 
 ⎭⎬
⎫
⎩⎨
⎧ ⎟⎠
⎞⎜⎝
⎛
∂
∂
∂
∂=∂
∂
⎪⎭
⎪⎬
⎫
⎪⎩
⎪⎨
⎧ ⎟⎠
⎞⎜⎝
⎛−
r
Cr
rr
D
z
C
R
rU 112
2
      (b.1) 
( ) 00, CrC =         (b.2) 
( ) 0, =zRC         (b.3) 
( ) 0,0 =∂
∂ z
r
C        (b.4) 
 
 Scaling, we define the following dimensionless variables: 
R
r=η             
0C
C=θ            
Pe*R
z=ζ       (b.5) 
where: 
D
UR2Pe =         (b.6) 
 
 Nondimensionalizing Eq. b.1-b.4, then, we obtain: 
( ) ⎟⎟⎠
⎞⎜⎜⎝
⎛
∂
∂
∂
∂=∂
∂− η
θηηηζ
θη 11 2        (b.7) 
( ) 10, =ηθ         (b.8) 
( ) 0,1 =ζθ         (b.9) 
( ) 0,0 =∂
∂ ζη
θ        (b.10) 
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 We first solve for the Sherwood number in the liposome concentration entrance 
region. Following the analysis of Deen [29], we define a new dimensionless variable: 
ηψ −=1         (b.11) 
Then Eq. b.7 becomes: 
                                               ( ) ψθψψθζθψψ ∂∂−−∂∂=∂∂− 1 12 2
2
2       (b.12) 
 
Performing an order-of-magnitude analysis on each term in Eq. b.12 per Deen 
[29] and retaining only the dominant terms, we obtain: 
         2
2
2 ψ
θ
ζ
θψ ∂
∂=∂
∂         (b.13) 
with boundary conditions: 
( ) 10, =ψθ         (b.14) 
( ) 0,0 =ζθ         (b.15) 
( ) 1, =∞ ζθ         (b.16) 
 
 Per Deen [29], we now apply the similarity method to solve this PDE. We assume 
that θ can be expressed as a function of an independent variable s: 
( )ζ
ψ
g
s =         (b.17) 
In terms of the similarity variable, Eq. b.13 becomes [29]: 
( ) 0'2 2222 =+ dsdggsdsd θθ        (b.18) 
 
Now requiring: 
                                                             
2
3constant'2 ≡=gg        (b.19) 
and 
( ) 00 =g         (b.20) 
we obtain: 
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( ) 3/1
2
9 ⎟⎠
⎞⎜⎝
⎛= ζζg        (b.21) 
3/1
3/1
9
2
ζ
ψ⎟⎠
⎞⎜⎝
⎛=s        (b.22) 
 
Eq. b.18 now becomes [29]: 
                                                                 03 22
2
=+
ds
ds
ds
d θθ        (b.23) 
with boundary conditions: 
( ) 00 =θ         (b.24) 
( ) 1=∞θ         (b.25) 
 
 Solving Eq. b.23, then: 
( ) ( ) ∫
∞
−
Γ−= s
t dtes
3
3/1
31θ        (b.26) 
 Per Deen [29], then, the Sherwood number can now be calculated as: 
( )
( ) ( )ζψ
θ
θθ
ψθ
ψ
ψ
gD
Rk
bw
c
3/1
62
/22
Sh
0
0
Γ=∂
∂=−
∂∂−=≡
=
=      (b.27) 
where θb = 1 because the liposome concentration in most of the vessel remains at the inlet 
concentration of 1. 
 
 Hence, in the liposome concentration entrance region: 
  1/3
3/1
Pe357.1Sh ⎟⎠
⎞⎜⎝
⎛=
z
R        (b.28) 
 
 We now solve for the Sherwood number in the liposome concentration fully 
developed region [29]. Again, the PDE of interest, slightly rearranged, with BCs is: 
( ) ⎟⎟⎠
⎞⎜⎜⎝
⎛
∂
∂
∂
∂
−=∂
∂
η
θηηηηζ
θ
21
1        (b.29) 
( ) 10, =ηθ         (b.8) 
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( ) 0,1 =ζθ         (b.9) 
( ) 0,0 =∂
∂ ζη
θ        (b.10) 
 
 Using the finite Fourier transform (FFT) method, we seek a solution of the form: 
         (b.30) ( ) ( ) (ηφζθζηθ n
n
n∑∞
=
=
1
, )
 The basis functions required are, per Deen [29]: 
                                                 ( ) ( )ηληφ nnn Ga=        (b.31) 
 The complete transformed problem is then: 
02 =+ nnnd
d θλζ
θ  , ( ) nnn b== φθ ,10       (b.32) 
 
 Solving, the overall solution is [29]: 
( ) (∑∞
=
−=
1
2
,
n
nnn Geba n ηλζηθ ζλ )       (b.33) 
 
 The Sherwood number can then be calculated as: 
  
1
22Sh
=∂
∂−=≡
ηη
θ
θb
c
D
Rk
       (b.34) 
Applying an overall species balance and integrating from ∞ to a finite value of ζ: 
   ( ) ( )∫∞ ∂∂−= ζ η
θζθ dvvb ,14        (b.35) 
where v is a dummy variable. Then, for ζ → ∞: 
( ) ( )ηλζηθ ζλ 111 21, Geba −→        (b.36) 
( ) ( )1111 21,1 ληλζη
θ ζλ
d
dGeba −→∂
∂       (b.37) 
( ) ( )1
1
11 214 ληλζθ
ζλ
d
dGebab
−−=       (b.38) 
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Using Eq. b.37-b.38 in Eq. b.34, then, the fully developed Sherwood number is 
simply: 
           ( ) 212
1Sh λ=∞         (b.39) 
which can be evaluated to yield: 
          ( ) 657.3Sh =∞         (b.40) 
 
 The equations above provide a representation of the distribution of (drug-
encapsulating or non-drug-encapsulating) liposomes in a blood vessel as a function of 
radial and axial position. The model hence, given three basic parameters: the radius R of 
the vessel, the mean velocity U of fluid flow in said vessel, and the diffusivity D of the 
liposomes in said vessel, allows one to compute the mass transfer coefficient kc and 
quantitatively model and predict the spatial distribution of liposomes in a blood vessel for 
many types of liposomes. The model can be refined by taking into account certain 
processes, shown in Figure 21, below, neglected in the above analysis for the sake of 
obtaining an analytical solution. 
 
 
Figure 21 – Schematic showing complicating factors potentially having an impact on 
the vascular distribution of liposomes. 
 
Model B.b Assumptions: incompressible Newtonian blood; Fick’s law valid; fully 
developed blood flow; unidirectional, axisymmetric blood flow; steady blood flow; large 
Péclet number (Pe = 2*U*R/D ~ 2*(0.001 m/s)*(5*10-6 m)/(10-12 m2/s) = 104 >> 1 in a 
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capillary); = constant; high rate of diffusion of liposomes through vessel wall 
(hence C ≈ 0 at r = R); constant parameters (D, R, µ, ρ); no reactions 
/dzdP
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